TY - JOUR
T1 - Pharmacokinetics and pharmacodynamics of vecuronium administered by bolus and infusion during halothane or balanced anesthesia
AU - Shanks, Colin A.
AU - Avram, Michael J
AU - Fragen, Robert J.
AU - O'Hara, Dorene A.
PY - 1987/1/1
Y1 - 1987/1/1
N2 - Vecuronium was administered to two patient groups as a single intravenous dose, 60 μg/kg, combined with an infusion, 1 μg/min/kg. Anesthesia was maintained for the first group with a halothane-nitrous oxide technique; the second group received fentanyl-barbiturate-tranqudizer-nitrous oxide. As the infusion ended, plasma vecuronium concentrations were 0.34 (± 0.10) μg/ml for the halothane group and 0.32 (± 0.07) μg/ml for the fentanyl group, associated with 93% (± 8) and 88% (± 10) twitch depression, respectively. Vecuronium plasma concentration-time data were combined with the simultaneous intensities of neuromuscular blockade to model the kinetic-dynamic values for each patient. For the halothane group the steady-state volume was 0.21 (±0.04) L/kg, the clearance was 2.9 (±0.1) ml/min/kg, and the elimination half-life was 100 (± 36) minutes; for the fentanyl group these were 0.20 (± 0.08) L/kg, 3.2 (±0.1) ml/min/kg, and 84 (±43) minutes, respectively. Plasma concentrations associated with 50% blockade averaged 0.2 μg/ml for both groups. Neither the pharmacoldnetics nor the pharmacodynamics of vecuronium in humans differed between these two patient groups.
AB - Vecuronium was administered to two patient groups as a single intravenous dose, 60 μg/kg, combined with an infusion, 1 μg/min/kg. Anesthesia was maintained for the first group with a halothane-nitrous oxide technique; the second group received fentanyl-barbiturate-tranqudizer-nitrous oxide. As the infusion ended, plasma vecuronium concentrations were 0.34 (± 0.10) μg/ml for the halothane group and 0.32 (± 0.07) μg/ml for the fentanyl group, associated with 93% (± 8) and 88% (± 10) twitch depression, respectively. Vecuronium plasma concentration-time data were combined with the simultaneous intensities of neuromuscular blockade to model the kinetic-dynamic values for each patient. For the halothane group the steady-state volume was 0.21 (±0.04) L/kg, the clearance was 2.9 (±0.1) ml/min/kg, and the elimination half-life was 100 (± 36) minutes; for the fentanyl group these were 0.20 (± 0.08) L/kg, 3.2 (±0.1) ml/min/kg, and 84 (±43) minutes, respectively. Plasma concentrations associated with 50% blockade averaged 0.2 μg/ml for both groups. Neither the pharmacoldnetics nor the pharmacodynamics of vecuronium in humans differed between these two patient groups.
UR - http://www.scopus.com/inward/record.url?scp=0023637570&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023637570&partnerID=8YFLogxK
U2 - 10.1038/clpt.1987.178
DO - 10.1038/clpt.1987.178
M3 - Article
C2 - 2889555
AN - SCOPUS:0023637570
SN - 0009-9236
VL - 42
SP - 459
EP - 464
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
IS - 4
ER -